High prescription drug prices

Issue Areas

Prescription Drug Policy

High prescription drug prices continue to make vital therapies unaffordable for many patients.

The broken prescription drug market with high prescription drug prices makes health care unaffordable for millions. But we have some policy options. Patients deserve access to drugs proven to work at prices we all can afford.

equitable outcomes for patients with high blood pressure
How do we promote equitable outcomes for patients with high blood pressure?

This Research Round-Up examines strategies for promoting equitable outcomes for patients with high blood pressure

Featured content
What is Kaiser Permanente’s different approach to prescription drugs?
Are biosimilar medications safe and effective?
Biosimilars at Kaiser Permanente: Lessons in successfully reducing spending on prescription drugs
Publications from PORTAL
How pharmaceutical marketing affects decisions about patient care
Restoring Provider Confidence In FDA-Approved Drugs
Evolving nature of evidence required by FDA to approve new drugs
Drug policy 101: Kaiser Permanente’s approach to pharmaceutical detailing
Building a bigger table for a more equitable drug development system
Series: Drug policy 101
The Medicaid Drug Rebate Program and the impact of “best price” rules
Drug policy 101: Pharmaceutical marketing tactics
The promise — and challenges — of gene therapy
Determining drug value: Let’s start with the evidence
Drug policy 101: Breaking down different types of drug products
Driving the conversation on drug value
How to save the patent system in 3 easy steps
It’s time to change drug companies’ harmful marketing practices
The price Is wrong: Why we need to curb prices on biologics to protect patients
A deeper dive: Recommendations for strengthening the FDA’s REMS program to protect patients
Drug policy 101: FDA risk evaluation and mitigation strategy (REMS)
Pills
Building Racial Equity into the Drug Development System: Clinical Trials, Access, and Affordability

This webinar is the second in a two-part series that looks at racial equity in the drug development system, from investment all the way through access. This forum will focus on equity in the patent system, clinical trials, healthcare delivery, and affordability.

Events
Building Racial Equity into the Drug Development System
Unpacking Drug Value
Addressing High Drug Pricing
No results found...